Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation
Abraham S. Kanate(HonorHealth), Mehdi Hamadani(Medical College of Wisconsin), Scot C. Remick(University Hospitals of Cleveland), Laura F. Gibson(West Virginia University), Deirdre Bulian(West Virginia University), Michael Craig(Edith Cowan University), Ayman Saad(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jame Abraham(Cleveland Clinic), Pamela Bunner(West Virginia University), Aaron Cumpston(West Virginia University Hospitals), Gerry Hobbs(West Virginia University), Sonia Leadmon(West Virginia University)
Cited by 10
Related Papers
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
|Transplantation and Cellular Therapy|2020|718
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
|Blood|2016|554
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
|Journal of Clinical Oncology|2019|441